DOI: http://dx.doi.org/10.18203/2349-2902.isj20213151

Surgical intervention as a curative major for secondary hypertension

Ramesh Mahadev Tambat, Venuprasad Narasimhaiah, Marshall David Collin, Nataraj Y. Sannappanavar, Nitin Kumar, Yogendra Shrestha, Jeet Bahadur Moktan

Abstract


Retroperitoneal functional paraganglioma is a rare type of neuroendocrine neoplasm which secrete excess catecholamines including epinephrine, norepinephrine, dopamine and their metabolites metanephrine, normetanephrine, 3-methoxytyramine respectively. Early diagnosis of functional paraganglioma is important because its removal is often curative. The extent of disease is evaluate using 2(18F)-fluoro-2 deoxy-D-glucose positron emission tomography (FDG-PET), where increased uptake of 18-FDG observed the mass. It is one of the rare curable causes of secondary hypertension. Here, we have presented the rare case of a young female who was recently diagnosed with hypertension and pain in abdomen, was later found to have functional paraganglioma.


Keywords


Functional paraganglioma, retroperitoneal paraganglioma, surgical management, Secondary hypertension, FDG-PET

Full Text:

PDF

References


Elder EE, Elder G, Larsson C. Pheochromocytoma and functional paraganglioma syndrome: no longer the 10% tumor. J Surg Oncol. 2005;89(3):193.

Amar L, Bertherat J, Baudin E, Ajzenberg C, Bressac-de Paillerets B, et al. Genetic testing in pheochromocytoma or functional paraganglioma. J Clin Oncol. 2005;23(34):8812-8.

Plouin PF, Gimenez-Roqueplo AP. Initial work-up and long term follow up in patients with phaeochromocytomas and paragangliomas. Best Pract Res Clin Endocrinol Metab. 2006;20:421-34.

Lenders JW, Eisenhofer G, Mannelli M, Pacak K. Phaeochromocytoma. Lancet. 2005;366:665-75.

Hescot S, Curras-Freixes M, Deutschbein T. Prognosis of malignant pheochromocytoma and paraganglioma (MAPP-Prono Study): a European network for the Study of Adrenal Tumors retrospective study. J Clin Endocrinol Metab. 2019; 104:2367-74.

Guerrero MA, Schreinemakers JM, Vriens MR. Clinical spectrum of pheochromocytoma . J Am Coll Surg. 2009;209:727-32.

Neumann HP, Bausch B, McWhinney SR. Germline mutations in nonsyndromic pheochromocytoma. N Engl J Med. 2002;346:1459-66.

Lenders JW, Duh QY, Eisenhofer G. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99:1915-42.

Renard J, Clerici T, Licker M, Triponez F: Pheochromocytoma and abdominal paraganglioma. J Visc Surg. 2011;148:409-16.

Lenders JW, Pacak K, Walther MM. Biochemical diagnosis of pheochromocytoma: which test is best?. JAMA. 2002;287:1427-34.

Eisenhofer G, Bornstein SR, Brouwers FM. Malignant pheochromocytoma: current status and initiatives for future progress. Endocr Relat Cancer. 2004;11:423-36.

Ferreira MA, Vilaverde J. A genética dos feocromocitomas e paragangliomas. Rev Port Endocrinol Diabetes Metab. 2014;9:29-35.

Turchini J, Cheung VKY, Tischler AS, De Krijger RR, Gill AJ. Pathology and genetics of phaochromo-cytoma and paraganglioma. Histopathol. 2018;72:97-105.

Eisenhofer G, Tischler AS, de Krijger RR. Diagnostic tests and biomarkers for pheochromocytoma and extraadrenal paraganglioma: from routine laboratory methods to disease stratification. Endocr Pathol. 2012;23:4-14.

John H, Ziegler WH, Hauri D, Jaeger P. Pheochromocytomas: can malignant potential be predicted? Urol. 1999;53:679-83.